Crinetics Pharmaceuticals (CRNX) Amortization of Deferred Charges (2019)

Crinetics Pharmaceuticals' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $703000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 13.53% year-over-year to $703000.0; the TTM figure through Mar 2026 stood at $2.9 million (changed N/A YoY), while the FY2025 annual figure was $3.0 million, down 0.92% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $703000.0, up from $654000.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $813000.0 in Q1 2025, with the low at $654000.0 in Q4 2025.
• The 3-year median for Amortization of Deferred Charges is $731000.0 (2024), against an average of $732250.0.
• The sharpest annual moves came in 2025 and 2026: Amortization of Deferred Charges dropped 13.83% in 2025, then slipped 13.53% in 2026.
• Crinetics Pharmaceuticals' Amortization of Deferred Charges stood at $759000.0 in 2024, then slipped by 13.83% to $654000.0 in 2025, then increased by 7.49% to $703000.0 in 2026.
• Business Quant data shows CRNX's Amortization of Deferred Charges at $703000.0 in Q1 2026, $654000.0 in Q4 2025, and $813000.0 in Q1 2025.